Neurocrine Biosciences Operating Lease Receivables (Current) decreased by 0.5% to $20.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.6%, from $22.00M to $20.10M.
operating_lease_receivable_current| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $13.20M | $12.40M | $18.80M | $23.60M | $22.00M | $21.10M | $20.20M | $20.10M |
| QoQ Change | — | -6.1% | +51.6% | +25.5% | -6.8% | -4.1% | -4.3% | -0.5% |
| YoY Change | — | — | — | +78.8% | +77.4% | +12.2% | -14.4% | -8.6% |